Story perspectives

Targeting ADAR1 Boosts Immune Response Against Glioblastoma

9/9/2025

Summary

Story summary

Researchers at Ludwig Lausanne identified ADAR1 as a key drug target for glioblastoma multiforme (GBM).
Disabling ADAR1 boosts immune responses and alters the tumor microenvironment, enhancing immune cell activity.
The study showed that ADAR1 loss slows tumor growth and improves survival in mouse models and human samples.
Future research aims to develop an ADAR1 inhibitor that effectively penetrates the brain for preclinical studies.
Targeting GBM cells expressing interferon-stimulated genes (ISGs) may lead to better therapies.

1 of 1

Story summary

Researchers at Ludwig Lausanne identified ADAR1 as a key drug target for glioblastoma multiforme (GBM).
Disabling ADAR1 boosts immune responses and alters the tumor microenvironment, enhancing immune cell activity.
The study showed that ADAR1 loss slows tumor growth and improves survival in mouse models and human samples.
Future research aims to develop an ADAR1 inhibitor that effectively penetrates the brain for preclinical studies.
Targeting GBM cells expressing interferon-stimulated genes (ISGs) may lead to better therapies.